Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT04939116

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Angion Biomedica Corp (from the registry)
Registry
  • NCT NCT04939116
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Georgia (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04939116. Randomized; triple masking; primary purpose treatment. Start 2021-12-24 (actual); primary completion 2023-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease
Condition
Glomerular Disease
Condition
Proteinuria
Intervention (Drug)
ANG-3070
Intervention (Drug)
Placebo
Lead sponsor
Angion Biomedica Corp (class: industry)

Record details

Record id
cardio:ct-nct04939116
Content hash
1c36c4b283595ad3ddd84e2dfc3c5815a34856e2ca004c4c6eccb34de29790fd